{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.4","value":"192.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.6","value":"216.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.5","value":"201.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"274"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.2","value":"208.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"}],"units":"Participants"}],"title":"Cycle 2, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.6","value":"213.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.7","value":"213.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"}],"units":"Participants"}],"title":"Cycle 3, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.7","value":"197.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86.2","value":"191.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.4","value":"168.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.6","value":"203.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.3","value":"222.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"Cycle 13, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"}],"units":"Participants"}],"description":"The Lower Limit of Quantitation (LLQ) of avelumab was 0.20 micrograms (mcg)/milliliter (mL). Data for this outcome measure was not collected for reporting group \"Best Supportive Care\", since avelumab was not administered in this arm.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG000","title":"Avelumab + Best Supportive Care (BSC)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Avelumab pharmacokinetic (PK) parameter analysis set: all participants who received at least one dose of avelumab and who had at least one post-dose concentration measurement above the LLQ for avelumab. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table; however, may not have evaluable data for every row. Here, 'n' signifies participants evaluable for this OM at specified time points.","reportingStatus":"POSTED","timeFrame":"End of avelumab infusion on Day 1 of Cycle 1, 2, 3, 5, 7, 9, 11, 13 and Day 15 of Cycle 1, 2, 3 (each cycle=28 days)","title":"Maximum Plasma Concentration (Cmax) of Avelumab","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (mcg/mL)"}